natgillin/translations-raw huggingface dataset:
Protective seal
Zaščitni pečat
PROTECTIVE SLEEVE CONTAINING WALLET
ZAŠČITNI OVOJ, KI VSEBUJE ZLOŽENKO
Protein binding in human plasma is approximately 87% at therapeutic concentrations, and thus interaction with other medicinal products, due to displacement is unlikely.
Vezava na plazemske beljakovine pri ljudeh je pri terapevtskih koncentracijah približno 87-%, zato so medsebojna delovanja drugimi zdravili zaradi izpodrivanja malo verjetna.
Protein binding in human plasma is approximately 87% at therapeutic concentrations, and thusinteraction with other medicinal products, due to displacement is unlikely.
Vezava na plazemske beljakovine pri ljudeh je pri terapevtskih koncentracijah približno 87-%, zato so medsebojna delovanja z drugimi zdravili zaradi izpodrivanja malo verjetna.
Protein binding of ceftiofur and its major metabolite is high, approximately 70% – 90%.
Vezava ceftiofurja in njegovega glavnega metabolita na proteine je visoka, okoli 70 – 90 %.
Protein binding of silodosin glucuronide is 91 %.
Vezava na beljakovine pri glukuronidnemu konjugatu silodozina je 91%.
Protein binding to human serum protein in vitro is  13%.
Vezava na humane serumske proteine in vitro je  13-odstotna.
Protein binding was not altered in subjects with mild or moderately impaired renal or hepatic function.
Pri osebah z blago ali zmerno okvaro ledvic ali jeter vezava na beljakovine ni bila spremenjena.
Protein in the urine
beljakovine v urinu
protein in the urine
beljakovine v urinu,
protein in the urine (abnormal urine test)
beljakovine v urinu (nenormalen urinski test)
Protein in the urine (also called ‘proteinuria’): Very common (may affect more than 1 in 10 people) – this is very commonly seen in tests.
Beljakovine v urinu (to imenujemo tudi "proteinurija"): zelo pogosto (pojavijo se lahko pri več kot 1 od 10 oseb) – To je zelo pogost izvid pri preiskavah.
Protein in the urine (found by testing)
beljakovine v urinu (ugotovijo se s testiranjem), žeja.
Protein in the urine (may show in your urine tests)
beljakovine v urinu (to se lahko pokaže pri preiskavah urina)
protein in the urine (proteinuria)
beljakovine v seču (proteinurija)
protein in the urine (proteinuria)
beljakovine v urinu (proteinurija)
Protein in the urine, increased urine, kidney problems.
proteini v urinu, večje izločanje urina, težave z ledvicami
Protein in the urine, occasionally severe and associated with side effects, such as swelling
beljakovine v urinu, ki jih je včasih veliko, kar je povezano z neželenimi učinki, na primer otekanjem,
protein in urine
beljakovine v urinu;
protein in urine.
bolezni ščitnice beljakovine v urinu
protein in your urine
beljakovine v urinu
Protein or blood in the urine, gallstones, painful urination
beljakovine ali kri v urinu, žolčni kamni, boleče odvajanje urina
Protein restriction and arginine supplementation may be indicated in case of low protein tolerance.
Pri slabem prenašanju proteinov je lahko umestno omejevanje vnosa proteinov in dodajanje arginina.
Protein Sequence change
Sprememba proteinskega zaporedja
Protein urine present
beljakovine v urinu
protein-losing gastroenteropathy, ileus, anal fistula
eksudativna gastroenteropatija, ileus, analna fistula
Proteinaceous particles may be present in the concentrate that appear as translucent to white, amorphous particles, some of which look fibrous.
V koncentratu so lahko prisotni beljakovinski delci, ki se lahko pojavijo kot prosojni do beli, amorfni delci, med katerimi so nekateri videti vlaknati.
proteins
SEKRETAGOGI INSULINA
proteins (albumin) in urine increase in levels of liver enzymes (ALT, AST) in the blood
beljakovine (albumin) v seču zvišanje ravni jetrnih encimov (ALT, AST) v krvi
proteins in urine
beljakovine v urinu
proteins in urine increased cholesterol in the blood
beljakovine v urinu; povišano raven holesterola v krvi.
proteinuria
glikozurija
proteinuria
proteinurija
Proteinuria (1),(3) Increased serum creatinine
proteinurija (1),(3) zvišanje kreatinina v serumu
Proteinuria (including increased blood creatinine)
proteinurija (vključno z povečanim kreatininom v krvi)
Proteinuria Renal failure
hematurija, proteinurija, odpoved ledvic
Proteinuria should be monitored by urine dipstick analysis and/or urinary protein creatinine ratio (UPCR) for the development or worsening of proteinuria before each aflibercept administration.
Proteinurijo je treba pred vsako uporabo aflibercepta kontrolirati z urinskimi testnimi trakovi in/ali z razmerjem urinskih beljakovin in kreatinina (UPCR – urinary protein creatinine ratio), da bi odkrili njen pojav ali poslabšanje.
Proteinuria*, blood creatinine increased, renal failure*
proteinurija*, zvišana koncentracija kreatinina v krvi, ledvična odpoved
proteinuria, blood creatinine increased, dysuria, haematuria
proteinurija, zvišana vrednost kreatinina v krvi, disurija, hematurija
Proteinuria, nephrolithiasis
proteinurija, nefrolitiaza
proteinuria, polyuria, renal impairment
proteinurija, poliurija, okvara ledvic
proteinuria, renal pain
Proteinurija, ledvične bolečine
Proteinuriaa
Proteinurijaa
Proteinuriaa,b
proteinurijaa,b
Proteinurial
proteinurijal
PROTELOS 2 g granules for oral suspension
PROTELOS 2 g zrnca za peroralno suspenzijo
PROTELOS is a medicine used to treat severe osteoporosis:
PROTELOS je zdravilo za zdravljenje hude osteoporoze:
PROTELOS is available in sachets containing yellow granules for oral suspension.
PROTELOS je na voljo v vrečkah, ki vsebujejo rumena zrnca za peroralno suspenzijo.
PROTELOS is contraindicated and must not be used in patients with :
Zdravilo PROTELOS je kontraindicirano in se ne sme predpisovati bolnikom:
PROTELOS is not intended for use in children and adolescents (below the age of 18).
Zdravilo PROTELOS ni namenjeno otrokom in mladostnikom (mlajšim od 18 let).
PROTELOS is only indicated for use in patients with severe osteoporosis at high risk of fracture, for whom treatment with other medicinal products approved for the treatment of osteoporosis is not possible due to, for example, contraindications or intolerance.
Zdravilo PROTELOS je indicirano samo za zdravljenje bolnikov s hudo osteoporozo z velikim tveganjem za zlome, pri katerih zdravljenje z drugimi zdravili, ki so odobrena za zdravljenje osteoporoze, zaradi kontraindikacij ali neprenašanja ni mogoče.
Protelos is unlikely to affect your ability to drive or use machines.
Ni verjetno, da bi zdravilo PROTELOS vplivalo na vašo sposobnost upravljanja vozil in strojev.
PROTELOS reduced the relative risk of new vertebral fracture by 41% over 3 years in the SOTI study (table 1).
V 3-letnem zdravljenju v študiji SOTI je zdravilo PROTELOS zmanjšal relativno tveganje novih zlomov vretenc za 41 % (preglednica 1).
PROTELOS should not be used during breast-feeding.
Zdravila PROTELOS se ne sme uporabljati med dojenjem.
PROTELOS should only be used with caution in:
Zdravilo PROTELOS je potrebno uporabljati previdno pri:
proteolytic activity:
proteolitična aktivnost:
ProteqFlu suspension for injection for horses
ProteqFlu suspenzija za injiciranje za konje
ProteqFlu-Te suspension for injection for horses
ProteqFlu-Te suspenzija za injiciranje za konje.
Prothrombin time
protrombinskega
Prothrombin time (PT) prolonged
podaljšanje protrombinskega časa (PČ)
Prothrombin time (≤1 X ULN)b
protrombinskega časa (≤ 1 krat ULN)b
prothrombin time or other
časa ali drugih primernih
Prothrombin time prolonged Pulmonary function test abnormal White blood cell count increased
podaljšan protrombinski čas, nenormalne preiskave pljučnega delovanja, povečanje števila levkocitov
prothrombin time.
protrombinskega časa.
Protocol 006 evaluated administration of Gardasil 9 to girls and women 12 through 26 years of age previously vaccinated with qHPV vaccine (N=921; 615 receiving Gardasil 9 and 306 receiving placebo).
Protokol 006 je ovrednotil uporabo cepiva Gardasil 9 pri deklicah in ženskah, starih od 12 do 26 let, predhodno cepljenih s qHPV cepivom (N = 921; 615 jih je prejelo cepivo Gardasil 9 in 306 placebo).
Protocol 006 evaluated the immunogenicity of Gardasil 9 in 921 girls and women (12 through 26 years of age) who had previously been vaccinated with qHPV vaccine.
Protokol 006 je ovrednotil imunogenost cepiva Gardasil 9 pri 921 deklicah in ženskah (starih od 12 do 26 let), predhodno cepljenih s qHPV cepivom.
Protocol 010 evaluated the immunogenicity of 2 doses of Gardasil 9 in girls and boys 9 through 14 years of age and 3 doses of Gardasil 9 in girls 9 through 14 years of age and women 16 through 26 years of age (N=1,518; 753 girls; 451 boys and 314 women).
Protokol 010 je ovrednotil imunogenost 2 odmerkov cepiva Gardasil 9 pri deklicah in dečkih, starih od 9 do 14 let, ter 3 odmerkov cepiva Gardasil 9 pri deklicah, starih od 9 do 14 let, in ženskah, starih od 16 do 26 let (N = 1.518; 753 deklic; 451 dečkov in 314 žensk).
Protocol 010 measured HPV antibody responses to the 9 HPV types after Gardasil 9 vaccination in the following cohorts: girls and boys 9 to 14 years old receiving 2 doses at a 6 month or 12-month interval (+/- 1 month); girls 9 to 14 years old receiving 3 doses (at 0, 2, 6 months); and women 16 to 26 years old receiving 3 doses (at 0, 2, 6 months).
Protokol 010 je ovrednotil odziv protiteles proti HPV na 9 tipov HPV po cepljenju s cepivom Gardasil 9 v naslednjih kohortah: deklice in dečki, stari od 9 do 14 let, ki so prejeli 2 odmerka v razmiku 6 mesecev ali 12 mesecev (+/- 1 mesec); deklice, stare od 9 do 14 let, ki so prejele 3 odmerke (v 0., 2. in 6. mesecu); in ženske, stare od 16 do 26 let, ki so prejele 3 odmerke (v 0., 2., 6. mesecu).
Protocol defined major bleeding
Večje krvavitve glede na protokol
Protocol defined non-inferiority of once daily dosing compared with twice daily dosing was demonstrated if the lower bound of the 95% confidence interval for the difference in proportion of subjects responding (once daily minus twice daily) excluded -12% at Week 48.
Pri 95% spodnji meji zaupanja za razliko pri deležu bolnikov, ki so se odzvali (enkrat dnevno minus dvakrat dnevno), izključujoč –12% v 48. tednu, je bilo enkrat dnevno odmerjanje v primerjavi z dvakrat dnevnim odmerjanjem neinferiorno kot definirano po protokolu.
Protocol defined non-inferiority of once-daily dosing compared with twice-daily dosing was demonstrated if the lower bound of the 95% confidence interval for the difference in proportion of subjects responding (once daily minus twice daily) excluded -12% at Week 48.
Pri 95% spodnji meji zaupanja za razliko pri deležu bolnikov, ki so se odzvali (enkrat dnevno minus dvakrat dnevno), izključujoč –12% v 48. tednu, je bilo enkrat dnevno odmerjanje v primerjavi z dvakrat dnevnim odmerjanjem neinferiorno kot definirano po protokolu.
Protocol No.
Številka protokola
Protocol submission: 3 months following EU Commission Decision
Predložitev protokola: 3 mesece po odločbi Evropske komisije
Protocol-specified dose regimen was application three times a day (TID) escalating to four times a day (QID) after two weeks, with downward adjustments for toxicity
S protokolom določeno odmerjanje je bila uporaba trikrat dnevno (TID), ki se je stopnjevala do štirikrat dnevno (QID) po dveh tednih, s prilagoditvijo navzdol pri toksičnosti
Protocol-specified dose regimen was application twice a day (BD) only, with downward adjustments for toxicity
S protokolom določeno odmerjanje je bila uporaba le dvakrat dnevno (BD), s prilagoditvijo navzdol pri toksičnosti
Protocols 005 and 007 evaluated Gardasil 9 concomitantly administered with vaccines recommended routinely in girls and boys 11 through 15 years of age (N=2,295).
Protokola 005 in 007 sta ovrednotila cepivo Gardasil 9, uporabljeno sočasno s cepivi, rutinsko priporočenimi za dečke in deklice, stare od 11 do 15 let (N = 2.295).
Proton pump
Antidepresivi:
PROTON PUMP INHIBITOR
Omeprazol*:
Proton pump inhibitor medicines (used to treat acid reflux disease and ulcers): omeprazole, esomeprazole, lansoprazole
zdravila, ki delujejo kot zaviralci protonske črpalke (uporabljajo se za zdravljenje gastroezofagealne refluksne bolezni in ulkusov):
PROTON PUMP INHIBITORS
benzodiazepina.
PROTON PUMP INHIBITORS
ZAVIRALCI PROTONSKE ČRPALKE
Proton Pump Inhibitors (PPI):
Zaviralci protonske črpalke (PPI)
Proton Pump Inhibitors (PPI):
Zaviralci protonske črpalke (PPI): Zaviralci protonske črpalke (PPI):
Proton Pump Inhibitors (PPI):
Zaviralci protonske črpalke (PPI; Proton Pump Inhibitors):
Proton pump inhibitors (PPIs)
Zaviralci protonske črpalke
Proton pump inhibitors and H2-receptor antagonists
Zaviralci protonske črpalke in antagonisti receptorjev H2
Proton pump inhibitors and H2-receptor antagonists (e.g. omeprazole or ranitidine) may reduce concentrations for co-administered protease inhibitors.
Zaviralci protonske črpalke in antagonisti receptorjev H2 (npr. omeprazol ali ranitidin) lahko zmanjšajo koncentracijo sočasno uporabljenih zaviralcev proteaz.
Proton pump inhibitors and H2-receptor antagonists (e.g. omeprazole or ranitidine) may reduce concentrations for co-administered protease inhibitors.
Zaviralci protonske črpalke in antagonisti receptorjev H2: zaviralci protonske črpalke in antagonisti receptorjev H2 (npr. omeprazol ali ranitidin) lahko zmanjšajo koncentracijo sočasno uporabljenih zaviralcev proteaz.
Proton pump inhibitors and H2-receptor antagonists (eg omeprazole or ranitidine) may reduce concentrations for co-administered protease inhibitors.
Zaviralci protonske črpalke in antagonisti receptorjev H2 (npr. omeprazol ali ranitidin) lahko zmanjšajo koncentracijo sočasno uporabljenih zaviralcev proteaz.
proton pump inhibitors is not
in zaviralcev protonske črpalke ni
Proton pump inhibitors – Data on the effect of concomitant administration of proton pump inhibitors (PPIs) with lasofoxifene is not available; thus, use of these agents with lasofoxifene should be considered with caution.
Inhibitorji protonske črpalke – Podatkov o vplivu sočasnega jemanja inhibitorjev protonske črpalke (PPI) z lasofoksifenom ni na voljo; zato je pri uporabi teh zdravil z lasofoksifenom potrebna previdnost.
Proton Pump Inhibitors:
Zaviralci protonske črpalke:
PROTOPIC 0.03% OINTMENT (10 g TUBE)
PROTOPIC 0,03% MAZILO (10 g TUBA)
PROTOPIC 0.03% OINTMENT (10 g, 30 g, 60 g CARTON)
PROTOPIC 0,03% MAZILO (10 g, 30 g, 60 g ŠKATLA)
PROTOPIC 0.03% OINTMENT (30 g, 60 g TUBE)
PROTOPIC 0,03% MAZILO (30 g, 60 g TUBA)
Protopic 0.03% ointment is indicated in adults, adolescents and children from the age of 2 years.
Zdravilo Protopic 0,03% je indicirano pri odraslih, mladostnikih in otrocih, starih 2 leti in več.
Protopic 0.03% ointment is used to treat moderate to severe atopic dermatitis (eczema) in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids and in children (2 years of age and older) who failed to respond adequately to conventional therapies such as topical corticosteroids.
Zdravilo Protopic 0,03% se uporablja za zdravljenje zmernega do hudega atopičnega dermatitisa (ekcema) pri odraslih, ki se na konvencionalne načine zdravljenja, kot so lokalni kortikosteroidi, ne odzovejo ustrezno ali jih ne prenašajo, in pri otrocih (starih 2 leti ali več), ki se na konvencionalne načine zdravljenja, kot so lokalni kortikosteroidi, ne odzovejo ustrezno.
Protopic 0.03% Ointment Tacrolimus monohydrate
Protopic 0,03% mazilo takrolimus monohidrat
Protopic 0.03% Ointment Tacrolimus monohydrate Cutaneous use
Protopic 0,03% mazilo takrolimus monohidrat dermalna uporaba
Protopic 0.1 % ointment is not approved for children younger than 16 years of age.
Zdravilo Protopic 0,1% ni odobreno za otroke mlajše od 16 let.
PROTOPIC 0.1% OINTMENT (10 g TUBE)
PROTOPIC 0,1% MAZILO (10 g TUBA)
PROTOPIC 0.1% OINTMENT (10 g, 30 g, 60 g CARTON)
PROTOPIC 0,1% MAZILO (10 g, 30 g, 60 g ŠKATLA)
PROTOPIC 0.1% OINTMENT (30 g, 60 g TUBE)
PROTOPIC 0,1% MAZILO (30 g, 60 g TUBA)
Protopic 0.1% ointment is used to treat moderate to severe atopic dermatitis (eczema) in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids.
Zdravilo Protopic 0,1% se uporablja za zdravljenje zmernega do hudega atopičnega dermatitisa (ekcema) pri odraslih, ki se na konvencionalne načine zdravljenja, kot so lokalni kortikosteroidi, ne odzovejo ustrezno ali jih ne prenašajo.
Protopic 0.1% Ointment Tacrolimus monohydrate
Protopic 0,1% mazilo takrolimus monohidrat
Protopic 0.1% Ointment Tacrolimus monohydrate Cutaneous use
Protopic 0,1% mazilo takrolimus monohidrat dermalna uporaba
Protopic alters the abnormal immune response and relieves the skin inflammation and the itch.
Zdravilo Protopic spremeni nenormalen imunski odziv in odpravi vnetje in srbenje kože.
Protopic is available in two strengths, Protopic 0.03 % and Protopic 0.1 % ointment.
Zdravilo Protopic je na voljo v dveh jakostih: kot Protopic 0,03% in Protopic 0,1% mazilo.
Protopic may be used on most parts of the body, including the face and neck and in the creases of your elbows and knees.
Zdravilo Protopic lahko uporabljate na večini delov telesa, tudi na obrazu, vratu in v komolčnih in kolenskih pregibih.
Protopic ointment has no or negligible influence on the ability to drive or use machines.
Zdravilo Protopic nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Protopic ointment has not been evaluated for its efficacy and safety in the treatment of clinically infected atopic dermatitis.
Učinkovitost in varnost zdravila Protopic nista raziskani za zdravljenje atopičnega dermatitisa, ki je klinično okužen.
Protopic ointment is not approved for children younger than 2 years of age.
Zdravilo Protopic ni odobreno za otroke mlajše od 2 let.
Protopic ointment may be used on any part of the body, including face, neck and flexure areas, except on mucous membranes.
Zdravilo Protopic se lahko uporabi na katerem koli delu telesa, tudi na obrazu, vratu in v pregibih, ne pa na sluznicah.
Protopic ointment should be applied as a thin layer to affected or commonly affected areas of the skin.
Na prizadete predele kože oziroma na predele kože, ki so navadno prizadeti, je treba nanesti tanko plast zdravila Protopic.
Protopic ointment should not be applied to lesions that are considered to be potentially malignant or pre-malignant.
Zdravila Protopic se ne sme nanašati na spremembe, ki bi lahko bile maligne ali predmaligne.
Protopic ointment should not be applied to lesions that are considered to be potentially malignant or pre-malignant.
Zdravilo Protopic se ne sme nanašati na spremembe, ki bi lahko bile maligne ali predmaligne.
Protopic ointment should not be applied under occlusion because this method of administration has not been studied in patients (see section 4.4).
Zdravila Protopic se ne sme uporabiti pod okluzijo, kajti takšen način uporabe ni bil preskušan na bolnikih (glejte poglavje 4.4).
Protopic ointment should not be used during pregnancy unless clearly necessary.
Zdravila Protopic ne smete uporabljati med nosečnostjo, razen če je nujno potrebno.
Protopic ointment should not be used in children aged below 2 years until further data are available.
Zdravila Protopic se ne sme uporabljati pri otrocih mlajših od 2 let, dokler ne bodo na voljo dodatni podatki.
Protopic should not be used in patients with congenital or acquired immunodeficiencies or in patients on therapy that cause immunosuppression.
Zdravila Protopic ne smete uporabljati pri bolnikih s prirojeno ali pridobljeno imunsko pomanjkljivostjo in bolnikih, ki prejemajo imunosupresivno terapijo.
Protopy 0.03% Ointment
Protopy 0,03% mazilo
PROTOPY 0.03% OINTMENT (10 g TUBE)
PROTOPY 0,03% MAZILO (10 g TUBA)
PROTOPY 0.03% OINTMENT (10 g, 30 g, 60 g CARTON)
PROTOPY 0,03% MAZILO (10 g, 30 g, 60 g ŠKATLA)
PROTOPY 0.03% OINTMENT (30 g, 60 g TUBE)
PROTOPY 0,03% MAZILO (30 g, 60 g TUBA)
Protopy 0.03% Ointment Tacrolimus monohydrate Cutaneous use
Protopy 0,03% mazilo Takrolimus monohidrat Za dermalno uporabo
Protopy 0.1% Ointment
Protopy 0,1% mazilo
PROTOPY 0.1% OINTMENT (10 g TUBE)
PROTOPY 0,1% MAZILO (10 g TUBA)
PROTOPY 0.1% OINTMENT (10 g, 30 g, 60 g CARTON)
PROTOPY 0,1% MAZILO (10 g, 30 g, 60 g ŠKATLA)
PROTOPY 0.1% OINTMENT (30 g, 60 g TUBE)
PROTOPY 0,1% MAZILO (30 g, 60 g TUBA)
Protopy 0.1% Ointment Tacrolimus monohydrate Cutaneous use
Protopy 0,1% mazilo Takrolimus monohidrat Za dermalno uporabo
Protopy is a white to slightly yellowish ointment.
Protopy je belo do rahlo rumenkasto mazilo.
Protopy may be used on most parts of the body, including the face and neck and in the creases of your elbows and knees.
Protopy se lahko uporablja na večini delov telesa, tudi na obrazu, vratu in v komolčnih in kolenskih pregibih.
Protopy ointment is not approved for children younger than 2 years of age.
Protopy ni odobren za otroke, mlajše od 2 let.
Protopy ointment should not be applied to lesions that are considered to be potentially malignant or pre-malignant.
Mazila Protopy se ne sme nanašati na spremembe, ki bi lahko bile maligne ali predmaligne.
Protopy ointment should not be used during pregnancy unless clearly necessary.
Zdravila Protopy ne smete uporabljati med nosečnostjo, razen če je nujno potrebno..
Protopy should be initiated by physicians with experience in the diagnosis and treatment of atopic dermatitis.
Zdravljenje s Protopyom morajo uvesti zdravniki, ki imajo izkušnje z diagnosticiranjem in zdravljenjem atopičnega dermatitisa.
Provenge (N=341)
Provenge (N = 341)
Provenge (N=65)
Provenge (N = 65)
Provenge 50 x 106 CD54+ cells/250mL dispersion for infusion.
Provenge 50 x 106 CD54+ celic/250 ml disperzija za infundiranje
PROVENGE dispersion for infusion.
PROVENGE disperzija za infundiranje
Provenge has a shelf life of 18 hours in the insulated container that is shipped to the medical facility where the infusion will be administered.
Rok uporabnosti zdravila Provenge je 18 ur v izoliranem vsebniku, poslanem na zdravstveni center, v katerem bo infundiranje potekalo.
Provenge has moderate influence on the ability to drive and use machines, as it may cause fatigue, dizziness, syncope, chills, and headache.
Zdravilo Provenge ima zmeren vpliv na sposobnost vožnje in upravljanja s stroji, saj lahko povzroči utrujenost, omotico, sinkopo, mrzlico in glavobol.
Provenge is a cancer medicine that is prepared specifically for each patient using their own immune cells (cells that form part of the body’s natural defences).
Provenge je zdravilo proti raku, ki se pripravi za vsakega bolnika posebej iz njegovih lastnih imunskih celic (tj. celic, ki so del naravnega obrambnega sistema telesa).
Provenge is a slightly cloudy dispersion of cream-to-pink colour and is supplied in a plastic bag with 3 sample ports.
Zdravilo Provenge je rahlo motna disperzija kremne do rožnate barve, dobavljena v plastični vrečki s 3 izhodi za vzorčenje.
Provenge is a type of advanced therapy medicine called a ‘somatic cell therapy product’.
Zdravilo Provenge je vrsta zdravila za napredno zdravljenje, ki se imenuje „zdravilo za somatsko celično zdravljenje“.
Provenge is an autologous cellular immunotherapy designed to induce an immune response targeted against prostatic acid phosphatase (PAP), an antigen expressed in most prostate cancers.
na prostatično kislo fosfatazo (PAP, prostatic acid phosphatase), to je antigen, izražen v večini rakov prostate.
Provenge is designed to stimulate your immune system, and therefore it may not be appropriate to be treated with Provenge if you are currently taking other treatments that could affect the ability of your immune system to respond to Provenge e.g., immunosuppressant medicines such as those used to treat or prevent organ rejection and certain medicines used to treat rheumatoid arthritis, multiple sclerosis, Crohn’s disease, and ulcerative colitis.
Zdravilo Provenge je zasnovano za spodbujanje vašega imunskega sistema, zato morda ni primerno, da se zdravite z zdravilom Provenge, če uporabljate druga zdravila, ki bi lahko vplivala na sposobnost vašega imunskega sistema, da se na zdravilo Provenge odzove, kot so npr. imunosupresivi, ki se uporabljajo za preprečevanje zavrnitve organa, ali nekatera zdravila za zdravljenje revmatoidnega artritisa, multiple skleroze, Crohnove bolezni in ulceroznega kolitisa.
Provenge is for use in men only.
Zdravilo Provenge se uporablja samo pri moških.